PVLA Stock Forecast & Price Target

Palvella Therapeutics is supported by a de-risked lead program in microcystic lymphatic malformations, where Phase 3 SELVA met its primary and prespecified secondary endpoints and the rolling NDA was completed on August 31, 2026, setting up a potential 1H27 approval as the first therapy for a condition with no FDA-approved treatment. Its commercial case is strengthened by a rare-disease launch team with prior success, payer conversations that have gone well, and a focused ~40-rep model aimed at ~400 high-volume centers, while management also sees cVM as a second opportunity with roughly twice the patients. Financially, the company raised $230M in 1Q26 to fund the next couple of years, and the work cited ~42K U.S. mLM patients, ~$2.1B and ~$1.7B in modeled worldwide peak sales for mLM and cVM, and a ~$4.6B implied market capitalization.

Palvella Therapeutics is viewed negatively because its lead programs rest on fragile clinical and regulatory footing: SELVA and TOIVA were small, single-arm or open-label studies, regulators have already pushed back on endpoints and bioavailability evidence, and the company still lacks filing acceptance, Priority Review, or Breakthrough Therapy support in cVM. Commercial assumptions also look stretched, with uncertain mLM market sizing, an assumed ~$170K net price and 35% peak penetration, and launch success dependent on reimbursement conversion and adherence that is unproven over years. Financially, it held $250.6M in cash and short-term investments at June 30, 2026, yet guided to only at least 12 months of runway, while negative free cash flow through 2028 and 8.0% to 9.8% royalties suggest further dilution and margin pressure.